Copyright 2020 The Science Publishers
All Rights Reserved for Website Design.
>    Suggest a new journal           

>   Manuscript editing services           

>   Ethical guidelines         

>   Terms and conditions
>    Home           

>   Jounals 

>   Join us       

>   Contact us

Home        About Us        Journals        Join Us        Services        Contact Us           




advanced
ISSN 2410-955X - An International Biannual Journal
BIOMEDICAL LETTERS
Immunoediting and tumor neoantigens that can impact the efficacy of immunotherapies
Katyayani Tatiparti, Mohd. Ahmar Rauf*

Department of Pharmaceutical sciences, Wayne state University, Detroit, MI, USA

Abstract
Immunoediting is by far the most serious challenge in the immunotherapies that are on the rise for Glioblastoma Multiforme (GBM). However, it is a double-edged sword because this process can be suppressive of the tumor too. Personalized medicine will succeed only if there are effective methods in place to address this challenge. A thorough understanding of the host immune system and the tumor cells heterogeneity and their mutual interactions is necessary. There is a lot of research being pursued in this direction. So far, the main aspect identified for developing immunotherapy for GBM is finding the balance between the immunoediting and the use of neoantigens for neoantigen-directed T-cell therapies.
A R T I C L E  I N F O

Received
January 13, 2020
Revised
March 31, 2020
Accepted
April 24, 2020

*Corresponding Author
Mohd. Ahmar Rauf
E-mail
ahmarrauf2@gmail.com

Keywords
Glioblastoma (GBM)
Neoantigens
Immunosurveillance
Immunoediting

Review article


2020 | Volume 6 | Issue 1: Special issue articles (Nanotechnology in Nanomedicine)